Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia

Overview

There is a lack of data on the prognostic importance of silent ischemia in totally asymptomatic subjects without history of coronary artery disease (CAD), and, particularly, on a possible benefit of medical therapy in such patients. SWISSI 1 therefore recruits totally asymptomatic subjects older than 40 years of age without any history of CAD but one cardiovascular risk factor with documented silent ischemia. Participants are randomized to open antianginal drug therapy and risk factor control versus only risk factor management and followed up for ≥ 10 years.

Full Title of Study: “Swiss Interventional Study on Silent Ischemia (SWISSI 1)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Detailed Description

Although there is still controversy regarding why ischemic episodes are symptomatic in some patients and completely asymptomatic in others, it is now widely accepted that silent ischemia, like symptomatic episodes, negatively affects prognosis. Silent ischemia may occur in totally asymptomatic patients without (type I) or with a history (type II) of an ischemic cardiac event and coexists with symptomatic episodes in many patients (type III). However, there is a lack of data on the prognostic importance of silent ischemia in totally asymptomatic subjects without history of coronary artery disease (CAD), i.e. silent ischemia type I, and, particularly, on a possible benefit of medical therapy in such patients. Reasons lie in the difficulty to identify such patients and their expected low event rates implying that large patient populations and/or long follow-up periods would be necessary to come to definite conclusions. Still, to address this problem, we perform SWISSI 1 which includes totally asymptomatic subjects older than 40 years of age without any history of CAD but one cardiovascular risk factor with documented silent ischemia. They are randomized to open antianginal drug therapy and risk factor control versus only risk factor management and followed up for ≥ 10 years.

Interventions

  • Drug: bisoprolol
  • Drug: amlodipine
  • Drug: molsidomine
  • Drug: acetylsalicylic acid

Clinical Trial Outcome Measures

Primary Measures

  • Combination of cardiac death, non-fatal myocardial infarction, unstable angina pectoris, and revascularization

Secondary Measures

  • Overall mortality
  • Cardiac death
  • Non-fatal myocardial infarction
  • Stable and unstable angina pectoris
  • Revascularization

Participating in This Clinical Trial

Inclusion Criteria

  • Documented silent myocardial ischemia type I – At least one cardiovascular risk factor Exclusion Criteria:

  • History of cardiovascular disease

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Luzerner Kantonsspital
  • Overall Official(s)
    • Paul Erne, MD, Principal Investigator, Department of Cardiology, Hospital Lucerne
    • Paul Erne, MD, Study Chair, Department of Cardiology, Hospital Lucerne

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.